bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (Nasdaq: BLUE) has announced the approval of inducement awards by the Compensation Committee of its Board of Directors. These awards include 242,500 restricted stock units (RSUs), with 100,000 RSUs granted to CFO James Sterling (grant date: September 30, 2024) and 142,500 RSUs granted to 19 other employees (grant date: October 1, 2024).
The Inducement Grants are subject to the terms of award agreements and the Company's 2021 Inducement Plan. The RSUs will vest equally over four years, with 25% vesting annually on the vesting date anniversary. These grants were made as inducement materials for new employees, including James Sterling, in accordance with NASDAQ Listing Rule 5635(c)(4).
bluebird bio, Inc. (Nasdaq: BLUE) ha annunciato l'approvazione di premi per induzione da parte del Comitato di Compensazione del suo Consiglio di Amministrazione. Questi premi includono 242.500 unità di azioni vincolate (RSUs), con 100.000 RSUs assegnate al CFO James Sterling (data di assegnazione: 30 settembre 2024) e 142.500 RSUs assegnate a 19 altri dipendenti (data di assegnazione: 1 ottobre 2024).
I Premi per Induzione sono soggetti ai termini degli accordi di assegnazione e al Piano di Induzione 2021 della Società. Le RSUs si matureranno equamente nel corso di quattro anni, con il 25% che matura annualmente all'anniversario della data di maturazione. Questi premi sono stati concessi come materiali di induzione per i nuovi dipendenti, incluso James Sterling, in conformità con la Regola di Quotazione NASDAQ 5635(c)(4).
bluebird bio, Inc. (Nasdaq: BLUE) ha anunciado la aprobación de premios de inducción por parte del Comité de Compensación de su Junta Directiva. Estos premios incluyen 242,500 unidades de acciones restringidas (RSUs), con 100,000 RSUs otorgadas al CFO James Sterling (fecha de otorgamiento: 30 de septiembre de 2024) y 142,500 RSUs otorgadas a 19 otros empleados (fecha de otorgamiento: 1 de octubre de 2024).
Los Premios de Inducción están sujetos a los términos de los acuerdos de otorgamiento y al Plan de Inducción 2021 de la Compañía. Las RSUs se distribuirán equitativamente a lo largo de cuatro años, con un 25% distribuyéndose anualmente en el aniversario de la fecha de distribución. Estos premios se otorgaron como materiales de inducción para nuevos empleados, incluido James Sterling, de acuerdo con la Regla de Cotización NASDAQ 5635(c)(4).
bluebird bio, Inc. (Nasdaq: BLUE)가 이사회의 보상위원회에 의해 유인 보상의 승인을 발표했습니다. 이러한 보상에는 242,500 제한 주식 단위(RSUs)가 포함되어 있으며, 이중 100,000 RSUs는 CFO James Sterling에게 (부여일: 2024년 9월 30일) 제공되며, 나머지 142,500 RSUs는 19명의 다른 직원에게 (부여일: 2024년 10월 1일) 제공됩니다.
유인 보상은 보상 계약의 조건 및 회사의 2021 유인 계획에 따라 다릅니다. RSUs는 4년에 걸쳐 균등하게 분배됩니다, 매년 분배 날짜 기념일에 25%가 분배됩니다. 이러한 보상은 James Sterling을 포함하여 신규 직원에 대한 유인 자료로 제공되었으며, NASDAQ 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
bluebird bio, Inc. (Nasdaq: BLUE) a annoncé l'approbation de récompenses d'incitation par le Comité de Rémunération de son Conseil d'Administration. Ces récompenses comprennent 242 500 unités d'actions restreintes (RSUs), dont 100 000 RSUs attribuées au CFO James Sterling (date d'attribution : 30 septembre 2024) et 142 500 RSUs attribuées à 19 autres employés (date d'attribution : 1er octobre 2024).
Les Récompenses d'Incitation sont soumises aux termes des accords d'attribution et au Plan d'Induction 2021 de la Société. Les RSUs seront acquises de manière égale sur quatre ans, 25 % étant acquises chaque année à l'anniversaire de la date d'acquisition. Ces attributions ont été faites comme des matériaux d'incitation pour les nouveaux employés, y compris James Sterling, conformément à la Règle de Cotation NASDAQ 5635(c)(4).
bluebird bio, Inc. (Nasdaq: BLUE) hat die Genehmigung von Induktionsprämien durch den Vergütungsausschuss seines Board of Directors bekannt gegeben. Diese Prämien umfassen 242.500 beschränkte Aktieneinheiten (RSUs), wobei 100.000 RSUs an CFO James Sterling (Zuteilungsdatum: 30. September 2024) und 142.500 RSUs an 19 weitere Mitarbeiter (Zuteilungsdatum: 1. Oktober 2024) vergeben wurden.
Die Induktionszusagen unterliegen den Bedingungen der Zuteilungsvereinbarungen und dem Induktionsplan 2021 des Unternehmens. Die RSUs werden über vier Jahre gleichmäßig aufgeteilt, wobei 25% jährlich am Jahrestag des Vesting-Datums fällig werden. Diese Zuwendungen wurden als Anreiz zur Einstellung neuer Mitarbeiter, einschließlich James Sterling, gemäß NASDAQ Listing Rule 5635(c)(4) gewährt.
- Attraction of new talent, including CFO James Sterling, with equity incentives
- Alignment of employee interests with company performance through RSU grants
- Potential dilution of existing shareholders due to new RSU issuance
The RSUs approved under the Inducement Grants vest equally over four years, with
The Company granted the RSUs as inducement materials to James Sterling and each other individual entering into employment with bluebird bio, Inc. in accordance with NASDAQ Listing Rule 5635(c)(4).
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004141404/en/
Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
Source: bluebird bio, Inc.
FAQ
How many restricted stock units (RSUs) did bluebird bio (BLUE) grant as inducement awards?
When will the RSUs granted by bluebird bio (BLUE) vest?
How many RSUs were granted to bluebird bio's (BLUE) CFO James Sterling?
Under which NASDAQ rule did bluebird bio (BLUE) grant these inducement awards?
